Dr Reddy’s Laboratories gained 4.8% driven by sale of API unit in Therapiva. Also, it receives USFDA approval for Aspirin and Dipyridamole post-trading hours can turn out positive tomorrow. On a technical chart, the stock is just 2% away from a rebreakout.
